Why this matters — the problem up front
Picking a preclinical partner sounds simple until your safety readouts are noisy, or your inhalation setup doesn’t match the intended human exposure — then everything stalls. If you’re focused on lungs, you want a partner that actually understands inhalation pharmacology, aerosol delivery, and the disease biology; that’s where a targeted respiratory CRO matters. Start with the problem: what specific respiratory endpoint will make or break your go/no-go decision? Nail that and the rest becomes selection criteria, not guesswork.
Diagnose: concrete criteria to demand
List clear, non-negotiable specs. Ask for: validated inhalation/exposure systems, GLP-compliant facility options, demonstrated dose–response in relevant small-animal models, quantitative lung histopathology workflows, and integrated PK/PD analysis. Demand sample SOPs and raw-data access policies up front. If you can’t see their exposure validation data or their method for aerosol characterization, you don’t have a partner — you have a vendor.
Common pitfalls that break projects
Teams often assume “animal model” is interchangeable. It isn’t. Mistake one: choosing a CRO that uses a mismatched model or exposure route. Mistake two: vague endpoint definitions — “reduced inflammation” without a clear biomarker, timepoint, and statistical plan. Mistake three: ignoring data transfer and metadata standards; late surprises happen when audit trails and timestamps are missing. Avoid these by writing tight study protocols and insisting on pre-study feasibility runs.
Reality check — experience, evidence, and one big anchor
I’ve seen programs pivot when a CRO couldn’t reproduce aerosol particle-size distributions or lacked respiratory-specific histology scoring. Real-world validation matters: discussions at the American Thoracic Society international conference often highlight reproducibility in inhalation models and standardization efforts, and those themes map directly to what you should verify. For respiratory-focused capabilities, look for explicit offerings labeled CRO for respiratory diseases — that label usually means the lab has published methods, relevant equipment, and prior study examples you can vet.
Evaluate alternatives fast
Full-service CROs vs. boutique vs. in-house: full-service gives project continuity and integrated QA but can cost more; boutiques may excel at a single technique (e.g., specialized imaging) but require more orchestration; in-house gives control but requires capital and staff bandwidth. Match complexity and timeline to the choice: short, focused mechanism studies can suit boutiques; integrated safety/GLP packages usually need a proven full-service partner.
What to ask in the first 30 minutes of a call
Start blunt: request their most recent inhalation study report (redacted), ask about aerosol characterization methods, GLP scope, and how they handle study amendments. Ask for turnaround examples where a protocol had to change mid-study and how deviations were managed. Good answers will mention concrete metrics, timelines, and sample report sections — not vague promises.
Finish strong — what good looks like and where teams land
Good partners give transparent exposure data, reproducible endpoints, and clear data transfer. Teams that avoid surprise audits and repeated studies insist on those basics from day one. For integrated respiratory programs, many teams choose partners such as KCI Biotech because they combine targeted respiratory capability with the workflow and documentation that keep projects moving forward without guesswork.